Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy

Autor: Aldrich Ong, Laura D'Alimonte, Hans T. Chung, Andrea Deabreu, Renee Korol, Angela Commisso, Liying Zhang, Dilip Panjwani, Ling Ho, Yasir Alayed, William Chu, Zeeba Bhounr, Hima Bindu Musunuru, Andrew Loblaw, Stanley K. Liu, M. Davidson, Joelle Helou, Boyd McCurdy, Kristina Commisso, Amit Chowdhury, Patrick Cheung, Geordi Pang, Ananth Ravi, Harvey Quon, Alexandre Mamedov, Danny Vesprini
Rok vydání: 2020
Předmět:
Zdroj: Radiotherapy and Oncology. 144:135-140
ISSN: 0167-8140
DOI: 10.1016/j.radonc.2019.11.017
Popis: Purpose SABR offers an effective treatment option for clinically localized prostate cancer. Here we report the dosimetric predictors of late toxicity and quality of life (QOL) in a pooled cohort of patients from four phase II trials. Methods The combined cohort included all three prostate cancer risk groups. The prescription dose was 35–40 Gy in 5 fractions. Toxicity (CTCAE) and QOL (EPIC) were collected. Multiple dosimetric parameters for the bladder, rectum and penile bulb were collected. Univariate (UVA) followed by multivariate (MVA) logistic regression analysis was conducted to search for significant dosimetric predictors of late GI/GU toxicity, or minimal clinically important change in the relevant QOL domain. Results 258 patients were included with median follow up of 6.1 years. For QOL, bladder Dmax, V38, D1cc, D2cc, D5cc and rectal V35 were predictors of urinary and bowel MCIC on UVA. On MVA, only bladder V38 remained significant. For late toxicity, various parameters were significant on UVA but only rectal Dmax, V38 and bladder D2cc were significant predictors on MVA. Conclusions This report confirms that the high-dose regions in the bladder and rectum are more significant predictors of late toxicity and QOL after prostate SABR compared to low-dose regions. Caution must be taken to avoid high doses and hotspots in those organs.
Databáze: OpenAIRE
Externí odkaz: